Abstract
The association of malignancy with systemic lupus erythematosus (SLE) has been investigated for years. The findings of cohort studies lend support for an increased risk of malignancy in SLE but are difficult to interpret definitively. In addition, several cohort studies have suggested an increased risk of non-Hodgkin's lymphoma but with imprecise estimation. There is inadequate evidence for any conclusions about the risk of solid tumors in these patients. A multicenter international research effort is in progress to elucidate these issues and to establish the role of exposures such as cytotoxic or immunomodulatory therapy. The recommendations advocated for cancer screening policies and for minimizing known risk factors for cancer in the general population should not be neglected in persons with SLE.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 351-358 |
| Number of pages | 8 |
| Journal | Current rheumatology reports |
| Volume | 4 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2002 |
Funding
The authors thank Dr. Syamal K. Datta for his invaluable assistance in reviewing this paper. Dr. Bernatsky is funded in part by the Canadian Arthritis Network and by the Singer Family Fund for Lupus Research. Dr. Clarke has been funded by The Arthritis Society and is a Canadian Institutes of Health Research investigator. Dr. Ramsey-Goldman is supported by an Arthritis Foundation Clinical Science grant and the National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health grants K24 AR02138 and P60 AR30692.
ASJC Scopus subject areas
- Rheumatology
